^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)

    i
    Other names: RG6264, RG 6264, RO7198574, Perjeta/Herceptin, RG-6264, RO-7198574, RO 7198574
    Company:
    Halozyme, Roche
    Drug class:
    HER2 inhibitor, HER2 dimerization inhibitor
    Related drugs:
    8d
    The value of time savings in breast cancer therapy for patients and healthcare providers: the subcutaneous injection of pertuzumab and trastuzumab fixed-dose combination at a tertiary care center in the UAE. (PubMed, J Comp Eff Res)
    PH FDC SC was associated with significant time savings for both patients and healthcare providers. The transition to SC administration unlocked 2468.25 clinical hours annually, translating into notable indirect cost reductions through optimized resource utilization and improved operational efficiency compared with IV administration.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    14d
    Improving public cancer care by implementing precision medicine in Norway (2023-507894-16-00)
    P1/2, N=1000, Recruiting, Oslo University Hospital HF | N=6000 --> 1000
    Enrollment change
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • imatinib • Alecensa (alectinib) • Cotellic (cobimetinib) • bortezomib • Piqray (alpelisib) • Zejula (niraparib) • Retevmo (selpercatinib) • Zykadia (ceritinib) • fulvestrant • Jemperli (dostarlimab-gxly) • Pemazyre (pemigatinib) • Tepmetko (tepotinib) • Tabrecta (capmatinib) • Erivedge (vismodegib) • melphalan • dactinomycin • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • hydroxyurea
    19d
    A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=258, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR positive
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    21d
    PA 2506: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (2025-522431-34-00)
    P1/2, N=1200, Not yet recruiting, Region Hovedstaden
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Xalkori (crizotinib) • erlotinib • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • gemcitabine • paclitaxel • 5-fluorouracil • capecitabine • Retevmo (selpercatinib) • albumin-bound paclitaxel • oxaliplatin • irinotecan • Pemazyre (pemigatinib) • axitinib • Erivedge (vismodegib) • leucovorin calcium • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    30d
    Doublecortin-Like Kinase 1 Expression in HER2-Positive Breast Cancer: Relation to Clinicopathological Characteristics and Response to Subcutaneous Injection of Pertuzumab-Trastuzumab (Phesgo) as a Part of Neoadjuvant Chemotherapy. (PubMed, Pathol Int)
    Dual blockade of HER2 using Phesgo is associated with pCR and better OS/PFS without adding more toxicity. High DCLK1 expression is related to unfavorable clinicopathologic parameters and poor response to neoadjuvant therapy, together with shorter OS/PFS.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    1m
    The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study. (PubMed, Int J Clin Oncol)
    The study met the co-primary endpoints of non-inferiority of cycle 7 serum Ctrough for pertuzumab and trastuzumab for PH FDC SC vs. P + H IV. tpCR rates and safety were comparable between arms. PH FDC SC may be a viable treatment option for Chinese patients with HER2-positive eBC.
    P3 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    1m
    DEMETHER: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=165, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2026 --> Apr 2027
    Enrollment closed • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    2ms
    ADEPT: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (clinicaltrials.gov)
    P2, N=393, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    2ms
    INAVO122: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=230, Recruiting, Hoffmann-La Roche | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 positive • PIK3CA mutation
    |
    tamoxifen • fulvestrant • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    2ms
    Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo® (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    4ms
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    4ms
    A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (clinicaltrials.gov)
    P3, N=200, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive
    |
    docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)